Learn to apply Bayes' theorem in financial forecasting for insightful, updated predictions. Enhance decision-making with ...
The FDA’s new draft guidance on Bayesian methodology signals a shift toward more flexible, data-driven clinical trial designs, enabling sponsors to use prior data and adaptive approaches to improve ...
The US Food and Drug Administration (FDA) is now “open to bayesian statistics,” contrasting this with the frequentist approach that the agency and the drug industry have historically relied on for ...
For more than 60 years, this blank slate approach has been the Food and Drug Administration’s gold standard — and for good ...
ACT Brief: Moving Beyond AI Pilots, FDA Advances Bayesian Trials, and Sites Strained by Trial Design
In today’s ACT Brief, we examine what will separate sponsors that scale AI beyond pilots in 2026, break down the FDA’s new draft guidance on Bayesian statistical methods in clinical trials, and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results